vs
Side-by-side financial comparison of NextPlat Corp (NXPL) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $12.8M, roughly 1.1× NextPlat Corp). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -40.2%, a 115.9% gap on every dollar of revenue. NextPlat Corp produced more free cash flow last quarter ($-339.0K vs $-2.1M).
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
NXPL vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.8M | $13.7M |
| Net Profit | $-5.1M | $10.4M |
| Gross Margin | 14.3% | — |
| Operating Margin | -28.9% | -86.5% |
| Net Margin | -40.2% | 75.7% |
| Revenue YoY | -21.1% | — |
| Net Profit YoY | -70.6% | 179.1% |
| EPS (diluted) | — | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.8M | $13.7M | ||
| Q3 25 | $13.8M | $19.1M | ||
| Q2 25 | $13.2M | $8.1M | ||
| Q1 25 | $14.5M | $2.9M | ||
| Q4 24 | $16.2M | — | ||
| Q3 24 | $15.4M | — | ||
| Q2 24 | $17.0M | — | ||
| Q1 24 | $17.5M | — |
| Q4 25 | $-5.1M | $10.4M | ||
| Q3 25 | $-2.2M | $-16.3M | ||
| Q2 25 | $-1.8M | $-15.8M | ||
| Q1 25 | $-1.3M | $-13.3M | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | $-4.2M | — | ||
| Q2 24 | $-5.3M | — | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | 14.3% | — | ||
| Q3 25 | 19.9% | — | ||
| Q2 25 | 21.8% | — | ||
| Q1 25 | 23.8% | — | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 23.2% | — | ||
| Q2 24 | 34.5% | — | ||
| Q1 24 | 27.8% | — |
| Q4 25 | -28.9% | -86.5% | ||
| Q3 25 | -14.5% | -10.1% | ||
| Q2 25 | -13.8% | -177.7% | ||
| Q1 25 | -10.2% | -472.7% | ||
| Q4 24 | -14.1% | — | ||
| Q3 24 | -52.1% | — | ||
| Q2 24 | -64.1% | — | ||
| Q1 24 | -10.5% | — |
| Q4 25 | -40.2% | 75.7% | ||
| Q3 25 | -15.9% | -85.4% | ||
| Q2 25 | -13.5% | -196.0% | ||
| Q1 25 | -9.2% | -452.7% | ||
| Q4 24 | -18.6% | — | ||
| Q3 24 | -27.4% | — | ||
| Q2 24 | -31.3% | — | ||
| Q1 24 | -8.5% | — |
| Q4 25 | — | $-3.74 | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | $-0.05 | $-0.18 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.7M | $137.5M |
| Total DebtLower is stronger | $1.3M | — |
| Stockholders' EquityBook value | $17.3M | $35.3M |
| Total Assets | $27.5M | $154.7M |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.7M | $137.5M | ||
| Q3 25 | $13.9M | $103.8M | ||
| Q2 25 | $16.6M | $121.6M | ||
| Q1 25 | $17.7M | $89.1M | ||
| Q4 24 | $20.0M | — | ||
| Q3 24 | $20.4M | — | ||
| Q2 24 | $24.9M | — | ||
| Q1 24 | $23.5M | — |
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $17.3M | $35.3M | ||
| Q3 25 | $21.4M | $-8.1M | ||
| Q2 25 | $23.5M | $7.1M | ||
| Q1 25 | $25.3M | $10.7M | ||
| Q4 24 | $27.3M | — | ||
| Q3 24 | $22.5M | — | ||
| Q2 24 | $26.5M | — | ||
| Q1 24 | $31.2M | — |
| Q4 25 | $27.5M | $154.7M | ||
| Q3 25 | $30.0M | $133.7M | ||
| Q2 25 | $31.0M | $133.8M | ||
| Q1 25 | $35.2M | $103.7M | ||
| Q4 24 | $37.1M | — | ||
| Q3 24 | $41.1M | — | ||
| Q2 24 | $51.5M | — | ||
| Q1 24 | $65.1M | — |
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 0.05× | — | ||
| Q1 24 | 0.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-302.0K | $-2.0M |
| Free Cash FlowOCF − Capex | $-339.0K | $-2.1M |
| FCF MarginFCF / Revenue | -2.6% | -15.3% |
| Capex IntensityCapex / Revenue | 0.3% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-302.0K | $-2.0M | ||
| Q3 25 | $-2.7M | $-17.5M | ||
| Q2 25 | $-1.0M | $-14.5M | ||
| Q1 25 | $-2.1M | $29.0M | ||
| Q4 24 | $-476.0K | — | ||
| Q3 24 | $-4.6M | — | ||
| Q2 24 | $2.3M | — | ||
| Q1 24 | $-2.7M | — |
| Q4 25 | $-339.0K | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-1.1M | $-14.9M | ||
| Q1 25 | $-2.1M | $29.0M | ||
| Q4 24 | $-508.0K | — | ||
| Q3 24 | $-4.7M | — | ||
| Q2 24 | $2.2M | — | ||
| Q1 24 | $-2.7M | — |
| Q4 25 | -2.6% | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | -8.0% | -184.0% | ||
| Q1 25 | -14.3% | 988.3% | ||
| Q4 24 | -3.1% | — | ||
| Q3 24 | -30.6% | — | ||
| Q2 24 | 13.2% | — | ||
| Q1 24 | -15.7% | — |
| Q4 25 | 0.3% | 0.7% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.1% | 5.0% | ||
| Q1 25 | 0.2% | 0.8% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
XLO
Segment breakdown not available.
